CBTCannabicitran (CBT-C)

Aliases.CBT-C · CBT · Cannabicitran

A minor tetracyclic cannabinoid. Present in trace amounts, captured by the French benzo[c]chromene clause.

Updated on 1 May 2026

Level of detail

Identifiers

Formula: C₂₁H₃₀O₄
Molar mass: 346.50 g·mol⁻¹
CAS: 11003-36-4
PubChem CID: 11551959
First described: 1971
Origin: Plant (tetracyclic benzo[c]chromene cannabinoid)
InChIKey: ZLYNXDIDWUWASO-UHFFFAOYSA-N

In plain terms

Cannabicitran (CBT) is a rare cannabinoid present in very small amounts in certain cannabis varieties. No known psychotropic effect.

Receptors and activity

CB1
Modulator
CB2
Modulator

Agonist
Partial agonist
Antagonist
Modulator
Inverse agonist

Hover over a row for the precise value (Ki, EC50…)

Subjective signature

Hover over an axis to read its definition.

Calm
25
Clarity
30
Sleep
15
Appetite
10
High
5

Editorial estimate, not clinical.

Pharmacology

Cannabicitran (CBT-C) was characterised by Bercht et al. (1973) as a tetracyclic structural isomer of THCA/CBLA. Saturated benzo[c]chromene scaffold. Present in trace amounts in certain varieties (Cannabis sativa indica). Negligible CB1/CB2 activity. France: its tetracyclic structure brings it under the **saturated benzo[c]chromene clause** introduced by the **ANSM Decision of 22 May 2024** - confirmation to be validated against the full text of the decision.